Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Perioperative SOX with apatinib and camrelizumab for resectable locally advanced gastric or gastroesophageal junction adenocarcinoma
ChiCTR1900028349Phase 3Not yet recruiting
- Sponsor
- Ruijin Hospital
- Start
- Dec 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of tegafur, oxaliplatin, Rivoceranib and camrelizumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma (3 arms), sponsored by Ruijin Hospital. Primary endpoint: Major pathologic response. Planned start Dec 2019; status: not yet recruiting.
02
Drugs
tegafuroxaliplatinRivoceranibcamrelizumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on ChiCTR1900028349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900028349.